AI-Powered Pharma Intelligence:Actionable Insights, Faster Decisions

Access DelveInsight's comprehensive library of pharma market reports, epidemiology studies, and competitive intelligence. Ask questions in natural language and get instant, citation-backed answers from our AI assistant, powered by deep pharma expertise.

What are the key efficacy endpoints in recent CAR-T trials for multiple myeloma?

AI Reasoning

Recent CAR-T trials in multiple myeloma primarily evaluate overall response rate (ORR) and duration of response (DOR) as primary endpoints. ^[1]

Median progression-free survival (PFS) ranges from 8.8 to 11.3 months across Phase 2 trials. ^{[1] Page 23}
Secondary endpoints include minimal residual disease (MRD) negativity rates and overall survival (OS). ^{[2] Page 45}

Sources: [1] Clinical Trial Report Q4-2024 • [2] Oncology Market Analysis

Start exploring today

Access DelveInsight's expert pharma intelligence and get AI-powered insights in seconds. Citation-backed answers to all your questions.

Try Market AI

DelveInsight's expertise meets conversational AI

Access comprehensive market reports, clinical trials, regulatory filings, and epidemiology studies from DelveInsight's expert research team. Our AI makes this wealth of pharma intelligence accessible through simple questions.

Powerful features designed for pharma intelligence

Ask Anything

Simply ask questions in plain English. Our AI assistant instantly searches across DelveInsight's comprehensive report library and delivers precise answers with citations, no manual searching required.

Searching DelveInsight library

What are the primary safety concerns in recent BCMA trials?

AI Answer

The primary safety concerns include cytokine release syndrome (CRS) and neurological toxicities. Grade 3+ CRS occurred in 8–12% of patients across trials.^[1]

[1] Clinical Trial Report – Page 34

Data Visualization

Optimistically Secure

Ease of Sharing

Rich Features

Customizable Dashboard

Tech Driven

Cost Saving

Instant Access

Speed Meets Precision

From Question to Strategic Insight in Seconds, Not Hours

DelveInsight's expert research team creates comprehensive market reports, clinical trials analysis, and regulatory intelligence covering 27 therapeutic areas. Our AI processes this wealth of knowledge and makes it instantly queryable. What used to take hours of manual reading now happens in seconds, with every claim backed by citations.

Whether you're analyzing competitor pipelines, extracting trial endpoints, or synthesizing regulatory guidance, Market AI delivers precise, citation-backed answers from DelveInsight's curated intelligence that help you make faster, more confident decisions.

AI in Clinical Trials: Transforming Drug Development

AI is being adopted to address longstanding trial challenges, including slow patient recruitment, high dropout rates, fragmented data, rising costs, and limited real-world generalizability. Discover real-world case studies from companies such as Deep6 AI, Octozi, Unlearn.AI, Medable, and Science 37 that demonstrate measurable gains in recruitment speed, data quality, virtual control arms, and patient engagement.

Read Full Analysis